Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PIROXICAM BETADEX
Chiesi Limited
20mg Milligram
Tablets
1997-08-14
IRISH MEDICINES BOARD ACT 1995 MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998 (S.I. NO.142 OF 1998) PA0743/010/002 Case No: 2032080 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to TRINITY-CHIESI PHARMACEUTICALS CHEADLE ROYAL BUSINESS PARK, HIGHFIELD, CHEADLE, SK8 3GY, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product BREXIDOL 20MG TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 25/01/2007 until 13/08/2007. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 26/01/2007_ _CRN 2032080_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Brexidol 20 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg piroxicam (as betadex) For excipients see 6.1. 3 PHARMACEUTICAL FORM Tablet Pale yellow, hexagonal tablet with a median score line on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As an anti-inflammatory analgesic in the treatment of: - arthritis and related disorders (e.g., rheumatoid arthritis, osteoarthritis, ankylosing spondylitis) - acute musculoskeletal disorders (e.g., bursitis, tendinitis) - acute gout - primary dysmenorrhoea - post-operative pain 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of Administrati Read the complete document